GSK submits EMEA MAA for pazopanib in RCC

UK drug major GlaxoSmithKline has submitted a Marketing  Authorization Application to the European Medicines Agency (EMEA)  for pazopanib as an oral therapy for patients with advanced and/or  metastatic renal cell carcinoma, the most common type of kidney cancer.  The incidence of RCC is rising throughout the world, with 208,000 new  cases diagnosed annually, and over 100,000 deaths. More than 10% of new  cases are diagnosed in western Europe. The oral, angiogenesis inhibitor  targets key proteins responsible for tumor growth and survival. The MAA  submission is based on positive results from a randomized, double-blind,  placebo-controlled Phase III study of pazopanib in treatment-naive and  cytokine-pre-treated patients with advanced RCC. The primary endpoint  was progression-free survival.